Brief: Royalty Pharma Q4 adjusted EBITDA USD 983 million
15/02/2023 12:07
Feb 15 (Reuters) - Royalty Pharma Q4 operating expenses USD 1,048 million. * Q4 adjusted EBITDA USD 983 million * Q4 pretax profit USD -610 million
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)